Vol. 2 No. 5 (2022)
Reimbursement Reviews

Enfortumab Vedotin (Padcev)

Published May 26, 2022

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses enfortumab vedotin (Padcev), 1.25 mg/kg, 20 mg and 30 mg single-use vials for IV infusion.
  • Indication: For the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and programmed death receptor 1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor therapy.